2014-03-21 21:22:47 UTC

Gastroenterology Podcast March 2014: Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Chronic Hepatitis C

A phase-3 study in the March issue of Gastroenterology examined the safety and efficacy of twice-daily telaprevir in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with cirrhosis. Dr. Kuemmerle discusses the results with first author Dr. Maria Buti; Plus, a rundown of top stories from this month's issue of GI and Hepatology News.

 

 

Buti M, Agarwal K, Horsmans Y, et al. Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C. Gastroenterology 2014; March; 146(3): 744-753
Abstract

 

 

Duration: 14.52m
Filetype: mp3
Bitrate: 96 KBPS
Frequency: 44100 HZ

More on Hepatitis C

Principles of GI for the NP & PA

Aug. 11, 2017

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Payer and Provider Workshops in HCV and HIV (New York, NY)

June 13, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free evening program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management.

Payer and Provider Workshops in HCV and HIV (Newark, NJ)

June 12, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free evening program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management.